Oxidative stress and oxidative DNA damage are early features of mild cognitive impairment and Alzheimer's disease (AD), occurring before the formation of classical AD neuropathology, and resulting from an imbalance between pro-and anti-oxidants. Astrocytes play a major neuroprotective role, producing high levels of anti-oxidants including metallothionein-I and -II (MT-I/II).
incorporating phosphorylated histone γH2AX. We have previously shown an association between the neuronal DDR and cognitive impairment, independent of AD pathology in the ageing brain , and demonstrated that increased levels of oxidative stress and the astrocyte DDR are an early event and not simply a secondary response to established AD pathology (Simpson, Ince, Haynes, et al., 2010 ).
Astrocytes play a major neuroprotective role, producing high levels of anti-oxidants (Ben Haim, Carrillo-de Sauvage, Ceyzeriat, & Escartin, 2015; Liddell, Robinson, Dringen, & Bishop, 2010) . Metallothioneins (MT) are low molecular weight cysteine-rich proteins with a high metal content that can protect against reactive oxygen species (ROS; Vasak & Meloni, 2011) . They comprise four subfamilies: MT-I and MT-II are present in most tissues, with MT-III and MT-IV expression confined to the central nervous system (CNS) and stratified squamous epithelium, respectively. While MT-I and -II have a similar structure, differing only by one amino acid and their ability to bind different metal ions, they are generally expressed in response to the same stimuli and perform the same function, so they are commonly grouped together and referred to as MT-I/II (Artells, Palacios, Capdevila, & Atrian, 2013) . Within the CNS, MT-I/II is predominantly expressed by astrocytes, but has also been detected in neurons, microglia and endothelial cells (Pedersen et al., 2009; West, Hidalgo, Eddins, Levin, & Aschner, 2008) , and is highly inducible in response to a variety of stimuli, including oxidative stress, neuroinflammation and toxic levels of metal ions (Andrews, 2000; Hidalgo et al., 2006; Manso, Adlard, Carrasco, Vasak, & Hidalgo, 2011) . MT-I/II gene expression is regulated by antioxidant response elements, and reduced expression of MT-I/II in cell models or knock out animals results in heightened sensitivity to oxidative stress (Pitt et al., 1997; Qu, Pi, & Waalkes, 2013) . MT-I/II is upregulated in AD (Adlard, West, & Vickers, 1998; Zambenedetti, Giordano, & Zatta, 1998) and is primarily associated with Aβ plaques in the hippocampus of several AD animal models Hidalgo et al., 2006) . Given the major role oxidative stress plays in the pathogenesis of neurodegenerative pathologies the present study evaluated MT-I/II expression in the temporal cortex of the Cognitive Function and Ageing Study (CFAS) neuropathology cohort, a well characterized large, ageing population-representative cohort which facilitates unbiased assessment of relationships between pathology and dementia, with the aim of assessing the relationship between MT-I/II and Alzheimertype pathology and the association with the astrocyte DDR in the aging human brain. In addition, the direct effect of oxidative stress on MT-I/II expression by human astrocytes was also assessed. assessed as part of the core CFAS neuropathology study using a modified protocol from the Consortium to Establish a Registry of Alzheimer's Disease (CERAD; wwws.cfas.ac.uk; Mirra, 1997) and Braak neurofibrillary tangle staging (Braak & Braak, 1991 were previously assessed in these cases (Simpson, Ince, Haynes, et al., 2010; Simpson, Ince, Lace, et al., 2010; Wharton et al., 2009) . A total of 78 participants were included in these analyses, where 48 were female.
| MATERIALS AND METHODS

| Human CNS cases
| Immunohistochemistry
Immunohistochemistry was performed using a standard avidin-biotin 
| Quantitative analysis of MT-I/II
Assessment of MT-I/II-specific immunoreactivity was performed by capturing bright-field microscopic images in three adjacent 350 μm-wide cortical ribbons, consisting of contiguous fields to cover the total cortical thickness through the apex of the gyrus, using a 20 × objective (Nikon Eclipse Ni-U microscope, Nikon, UK) and analyzed using the Analysis^D software (Olympus Biosystems, Watford, UK). The image was thresholded and the immunoreactive area of the field determined per total area examined.
| Primary human astrocytes
Previously characterized (Garwood et al., 2015) , human primary astro- 
| Immunocytochemistry
Cells were fixed in 4% paraformaldehyde in PBS for 5 min at 37 C, then permeabilized (0.3% Triton X-100 in PBS) and blocked with 3% bovine serum albumin for 20 min at RT. Cells were incubated with MT-I/II (1:100) for 60 min at RT, followed by biotinylated secondary antibody, and visualized with streptavidin alexa fluor 488 (1:500).
Nuclei were counterstained with Hoechst 33342, and the staining visualized using a Nikon Eclipse Ni-U microscope (Nikon, Kingston upon Thames, UK).
| Quantitative real-time polymerase chain reaction (qPCR)
Cultured astrocytes were washed with PBS and lysed in 110 μl
(1 ml/10 cm 2 ) Trizol (Thermoscientific, UK). RNA was isolated using the Direct-Zol RNA Miniprep Kit with Zymo-Spin IIC Columns (Zymo, Irvine, CA) and total RNA (500 ng) was incubated at 25 C for 5 min and reverse transcribed at 42 C for 30 min followed by incubation at 85 C for 5 min in a reaction mix containing qScript (Quanta Biosciences, Gaithersburg, MD). qPCR was performed using IDT PrimeTime qPCR assays (Integrated DNA Technologies, UK) containing 50 ng cDNA, 500 nM primers, 250 nM probe, and Brilliant qPCR mix (Agilent, UK). Primers for MT2A and β-actin were designed to span between adjacent exons (MT2A Primer 1:
. Following denaturation at 95 C for 3 min the products were amplified (40 cycles at 95 C for 10 s and 60 C for 30 s) using a CFX384 Touch RT PCR detection system (Bio-Rad, UK). β-actin was amplified on each plate to normalize expression levels of target genes between different samples using the ΔΔCt calculation (ABI) and to assess assay reproducibility. 
| Statistical analysis
| DISCUSSION
Oxidative stress and the associated oxidative-induced damage plays a key role in the initiation and progression of AD (Keller et al., 2005; Nunomura et al., 2006; Nunomura et al., 2001 ). In the current study we demonstrate that MT-I/II expression is predominantly associated with astrocytes in the ageing brain. Expression of this anti-oxidant does not correlate with Alzheimer-type pathology but does relate to the astrocyte response to oxidative DNA damage in vivo, and is induced in human astrocytes in response to oxidative stress in vitro. Within the aging temporal cortex MT-I/II is predominantly associated with astrocytes, supporting previous studies in AD (Adlard et al., 1998; Zambenedetti et al., 1998) . In contrast to these studies which examined a small number of cases and report MT-I/II is exclusively associated with astrocytes, we demonstrate MT-I/II is also weakly associated with pyramidal neurons in cases with high levels of local tau pathology in a small proportion of a much larger cohort. MT-I/II is generally considered an intracellular protein which is primarily localized in the cytoplasm of astrocytes, however MT-I/II can be released into the extracellular matrix and internalized by neurons via low density lipoprotein receptors, decreasing phosphorylation of several intraneuronal kinases implicated in pro-inflammatory processes and apoptosis, and promoting neurite outgrowth and neuronal survival (Ambjorn et al., 2008; Asmussen, Von Sperling, & Penkowa, 2009; Chung et al., 2008; Fitzgerald et al., 2007) . Furthermore, MT-I/II expression is induced in neurons in the hippocampus of animal models of multiple sclerosis (Grubic Kezele, Blagojevic Zagorac, Jakovac, Domitrovic, & Radosevic-Stasic, 2017) , and in adult rats following systemic administration of kainic acid (Kim et al., 2003) . Whether the immunopositive neurons detected in the current study are a result of neuronal uptake of MT-I/II or induction of MT-I/II expression is unknown.
In the current study we demonstrate MT-I/II expression is not a specific astrocyte response to local Alzheimer type pathology. This finding conflicts with rodent models of AD which show prominent upregulation of MT-I/II associated with Aβ plaques Hidalgo et al., 2006) Oxidative stress and metal ion dyshomeostasis are key features of AD pathology and may contribute to the pathogenesis of disease. Zinc plays a critical role in memory formation, regulating neuronal communication in the hippocampus (Pan et al., 2011; Wang et al., 2010) , and is highly concentrated within Aβ plaques, with depleted levels in the surrounding parenchyma (Dong et al., 2003; Lovell, Robertson, Teesdale, Campbell, & Markesbery, 1998; Sayre et al., 2000; Suh et al., 2000) .
Both zinc deficiency and zinc overload elicit oxidative stress that can lead to neuronal death (Sekler & Silverman, 2012; Wang et al., 2010) .
MT play a neuroprotective role against ROS damage in AD, scavenging hydroxyl radicals, superoxide anions, hydrogen peroxide and reactive nitrogen radicals, and are generally considered more effective antioxidants than superoxide dismutase, catalase or glutathione peroxidase is located in the cytoplasm, however nuclear translocation of MT-I/II has been shown to occur in response to ultra-violet damage (Hanada, Tamai, Sawamura, Hashimoto, & Muramatsu, 1998; Jourdan et al., 2002) and cytokine activation (Spahl, Berendji-Grun, Suschek, KolbBachofen, & Kroncke, 2003) . In addition to increased expression of MT-I/II in the cytoplasmic compartment of human astrocytes in response to oxidative stress in vitro, we also demonstrate increased expression in the nuclear compartment, where it likely plays a role in the requirement of zinc for nuclear metalloenzymes and transcription factors.
While recent research has primarily focused on enhancing MT-III as a therapeutic strategy for AD (Aikins et al., 2017; Roy et al., 2017) , to medical research, which has made this study possible.
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